IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center)

N/A

Report date: 2023/02/22 10:38:25

Base Information

Drug NameIL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center)
Drug Alias NameIL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM CellsIL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocyte therapyIL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM LymphocytesIL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cell therapyIL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells +[11] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-IL13RA2T lymphocyte replacements
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsUveal melanomaSkin MelanomaSolid tumours +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUclas Jonsson Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUclas Jonsson Comprehensive Cancer CenterNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsUveal melanomaSkin MelanomaSolid tumours +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A